Long-acting parenteral drug delivery systems for the treatment of chronic diseases

AB Jindal, AR Bhide, S Salave, D Rana… - Advanced Drug Delivery …, 2023 - Elsevier
The management of chronic conditions often requires patients to take daily medication for an
extended duration. However, the need for daily dosing can lead to nonadherence to the …

Prodrug approaches for the development of a long-acting drug delivery systems

ST Chien, IT Suydam, KA Woodrow - Advanced Drug Delivery Reviews, 2023 - Elsevier
Long-acting formulations are designed to reduce dosing frequency and simplify dosing
schedules by providing an extended duration of action. One approach to obtain long-acting …

Recent advances in lipid-based long-acting injectable depot formulations

R Sharma, S Yadav, V Yadav, J Akhtar, O Katari… - Advanced drug delivery …, 2023 - Elsevier
Long-acting injectable (LAIs) delivery systems sustain the drug therapeutic action in the
body, resulting in reduced dosage regimen, toxicity, and improved patient compliance. Lipid …

Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges

V Agrahari, SM Anderson, MM Peet… - Expert opinion on …, 2022 - Taylor & Francis
Introduction Poor or inconsistent adherence to daily oral pre-exposure prophylaxis (PrEP)
has emerged as a key barrier to effective HIV prevention. The advent of potent long-acting …

[HTML][HTML] Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection

MU Nayan, B Sillman, M Hasan, S Deodhar… - Advanced Drug Delivery …, 2023 - Elsevier
Adherence to daily oral antiretroviral therapy (ART) is a barrier to both treatment and
prevention of human immunodeficiency virus (HIV) infection. To overcome limitations of life …

HIV-1 integrase strand transfer inhibitors and neurodevelopment

EG Foster, HE Gendelman, AN Bade - Pharmaceuticals, 2022 - mdpi.com
Children born to mothers, with or at risk, of human immunodeficiency virus type-1 (HIV-1)
infection are on the rise due to affordable access of antiretroviral therapy (ART) to pregnant …

Long-acting dolutegravir formulations prevent neurodevelopmental impairments in a mouse model

EG Foster, B Sillman, Y Liu, M Summerlin… - Frontiers in …, 2023 - frontiersin.org
The World Health Organization has recommended dolutegravir (DTG) as a preferred first-
line treatment for treatment naive and experienced people living with human …

Polymer Delivery Systems for Long-Acting Antiretroviral Drugs

MU Nayan, S Panja, A Sultana, LA Zaman, LK Vora… - Pharmaceutics, 2024 - mdpi.com
The success of long-acting (LA) drug delivery systems (DDSs) is linked to their
biocompatible polymers. These are used for extended therapeutic release. For treatment or …

Polymer–prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine

C Liu, FY Hern, A Shakil, K Temburnikar… - Journal of Materials …, 2023 - pubs.rsc.org
Circulating, soluble polymer–drug conjugates have been utilised for many years to aid the
delivery of sensitive, poorly-soluble or cytotoxic drugs, prolong circulation times or minimise …

3D printing of dolutegravir-loaded polylactide filaments as a long-acting implantable system for HIV treatment

BNV Hari, T Makowski, P Sowiński, A Domańska… - International Journal of …, 2024 - Elsevier
Abstract 3D printing was used to prepare implantable systems or tablets loaded with
dolutegravir to explore their potential as long-acting implantables (LAIs). Our strategy relies …